Pune: The Food and Drug Administration (FDA) has permanently canceled the production license of Johnson’s baby powder produced by multinational company Johnson and Johnson’s Pvt. Ltd. from September 15.

Analysis of the samples collected from Pune and Nashik by the government’s drug control laboratory in Mumbai revealed that the product was substandard.

Click for more on FDA Maharshtra

The baby powder is used for newborn children. Defects have been found in its production process.

The pH of the products was not up to the requisite standard, which lead to damage to the skin of newborns as well as small children.

Hence, the continuation of its production was not in the public interest and the permission was canceled, said, officials.

The FDA has issued a show-cause notice to the company.

A company has also been asked to recall this product from the market. The company had not accepted the report of the government analyst and had submitted an application for re-testing in a drug laboratory in the courts of Pune and Nashik.

NPPA fixes Retail Prices of 37 Formulations: September 2022

High Court: Marketing Companies will have a right to the Trademark

Govt is in final stage to cap margins of key medicines

USFDA approves Terlipressin for injection to treat Kidney function 

PCI to amend Exit Examination Regulation for Diploma in Pharmacy

USFDA gives tentative approval for Sugammadex Injection

Drug alert: 45 out of 1330 samples declared as NSQ in August 2022

Panel recommends a separate legislation for Medical Devices

Govt adds 34 drugs in NLEM – National List of Essential Medicines

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/?p=41165